• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用纳米载体递送系统增强自然杀伤T细胞的佐剂功能：在抗癌免疫治疗中的应用。

Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

作者信息

Ghinnagow Reem, Cruz Luis Javier, Macho-Fernandez Elodie, Faveeuw Christelle, Trottein François

机构信息

Univ. Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France.

Centre National de la Recherche Scientifique, UMR 8204, Lille, France.

出版信息

Front Immunol. 2017 Jul 27;8:879. doi: 10.3389/fimmu.2017.00879. eCollection 2017.

DOI:10.3389/fimmu.2017.00879
PMID:28798749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5529346/
Abstract

Type I natural killer T (NKT) cells have gained considerable interest in anticancer immune therapy over the last decade. This "innate-like" T lymphocyte subset has the unique ability to recognize foreign and self-derived glycolipid antigens in association with the CD1d molecule expressed by antigen-presenting cells. An important property of these cells is to bridge innate and acquired immune responses. The adjuvant function of NKT cells might be exploited in the clinics. In this review, we discuss the approaches currently being used to target NKT cells for cancer therapy. In particular, we highlight ongoing strategies utilizing NKT cell-based nanovaccines to optimize immune therapy.

摘要

在过去十年中，I型自然杀伤T（NKT）细胞在抗癌免疫治疗方面引起了广泛关注。这种“固有样”T淋巴细胞亚群具有独特的能力，能够识别与抗原呈递细胞表达的CD1d分子相关的外来和自身来源的糖脂抗原。这些细胞的一个重要特性是能够连接固有免疫和获得性免疫反应。NKT细胞的佐剂功能可能在临床上得到应用。在这篇综述中，我们讨论了目前用于靶向NKT细胞进行癌症治疗的方法。特别是，我们重点介绍了利用基于NKT细胞的纳米疫苗来优化免疫治疗的现行策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8747/5529346/ba6631b502cd/fimmu-08-00879-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8747/5529346/1df1d5742062/fimmu-08-00879-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8747/5529346/ba6631b502cd/fimmu-08-00879-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8747/5529346/1df1d5742062/fimmu-08-00879-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8747/5529346/ba6631b502cd/fimmu-08-00879-g002.jpg

相似文献

1
Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.使用纳米载体递送系统增强自然杀伤T细胞的佐剂功能：在抗癌免疫治疗中的应用。
Front Immunol. 2017 Jul 27;8:879. doi: 10.3389/fimmu.2017.00879. eCollection 2017.
2
Immunotherapeutic strategies targeting natural killer T cell responses in cancer.针对癌症中自然杀伤T细胞反应的免疫治疗策略。
Immunogenetics. 2016 Aug;68(8):623-38. doi: 10.1007/s00251-016-0928-8. Epub 2016 Jul 8.
3
Regulation of immune responses by CD1d-restricted natural killer T cells.CD1d 限制性自然杀伤 T 细胞对免疫反应的调节
Immunol Res. 2004;30(2):139-53. doi: 10.1385/IR:30:2:139.
4
Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.利用基于细胞的和纳米载体疫苗优化自然杀伤 T 细胞介导的癌症免疫疗法。
Cancer Res. 2014 Mar 15;74(6):1632-8. doi: 10.1158/0008-5472.CAN-13-3504. Epub 2014 Mar 5.
5
NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.NKT细胞糖脂激动剂作为合成疫苗中的佐剂。
Carbohydr Res. 2017 Nov 27;452:78-90. doi: 10.1016/j.carres.2017.10.006. Epub 2017 Oct 17.
6
Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.不同自然杀伤T细胞亚群之间的交叉调节影响对自身和外来抗原的免疫反应。
J Cell Physiol. 2009 Feb;218(2):246-50. doi: 10.1002/jcp.21597.
7
Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.自然杀伤T细胞对GD3神经节苷脂的精细特异性及GM3作为自然杀伤T细胞抑制性配体的鉴定。
Immunology. 2008 Jan;123(1):145-55. doi: 10.1111/j.1365-2567.2007.02760.x.
8
Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective.自然杀伤性T细胞：生态-进化-发育生物学视角
Front Immunol. 2017 Dec 22;8:1858. doi: 10.3389/fimmu.2017.01858. eCollection 2017.
9
Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.用α-半乳糖神经酰胺致敏的小鼠中，不变的Vα14自然杀伤T细胞（Vα14i NKT细胞）扩增阶段的表型和功能改变。
Immunology. 2005 Sep;116(1):30-7. doi: 10.1111/j.1365-2567.2005.02193.x.
10
NKT and tolerance.自然杀伤T细胞与免疫耐受
Methods Mol Biol. 2011;677:193-206. doi: 10.1007/978-1-60761-869-0_14.

引用本文的文献

1
Engineering customized nanovaccines for enhanced cancer immunotherapy.工程定制纳米疫苗以增强癌症免疫治疗
Bioact Mater. 2024 Mar 10;36:330-357. doi: 10.1016/j.bioactmat.2024.02.028. eCollection 2024 Jun.
2
Harnessing NKT cells for vaccination.利用自然杀伤T细胞进行疫苗接种。
Oxf Open Immunol. 2021 Jun 19;2(1):iqab013. doi: 10.1093/oxfimm/iqab013. eCollection 2021.
3
cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice.环状二核苷酸（cGAMP）佐剂多价流感mRNA疫苗通过小鼠皮肤接种诱导广泛的保护性免疫。

本文引用的文献

1
Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.将自然杀伤T细胞（NKT）激动剂α-半乳糖神经酰胺与肿瘤抗原共同递送至交叉呈递树突状细胞可打破对自身抗原的耐受性并促进抗肿瘤反应。
Oncoimmunology. 2017 Aug 18;6(9):e1339855. doi: 10.1080/2162402X.2017.1339855. eCollection 2017.
2
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.不变自然杀伤 T 细胞有助于慢性淋巴细胞白血病的监测和预后。
Blood. 2017 Jun 29;129(26):3440-3451. doi: 10.1182/blood-2016-11-751065. Epub 2017 May 2.
3
Mol Ther Nucleic Acids. 2022 Nov 9;30:421-437. doi: 10.1016/j.omtn.2022.10.024. eCollection 2022 Dec 13.
4
Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.基于组织驻留固有免疫细胞的疗法：癌症治疗免疫疗法策略的基石
Front Cell Dev Biol. 2022 May 26;10:907572. doi: 10.3389/fcell.2022.907572. eCollection 2022.
5
The Role of Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions.检测药物特异性介质释放细胞在诊断严重皮肤不良反应不同表型中的作用
Allergy Asthma Immunol Res. 2021 Nov;13(6):896-907. doi: 10.4168/aair.2021.13.6.896.
6
Carbohydrate Conjugates in Vaccine Developments.疫苗研发中的碳水化合物缀合物
Front Chem. 2020 Apr 15;8:284. doi: 10.3389/fchem.2020.00284. eCollection 2020.
7
ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.ICAM3-Fc 优于针对树突状细胞的受体特异性抗体靶向纳米颗粒进行交叉呈递。
Molecules. 2019 May 12;24(9):1825. doi: 10.3390/molecules24091825.
8
CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.基于CD1d不变自然杀伤T细胞的癌症免疫疗法：α-半乳糖神经酰胺及其他。
Front Immunol. 2018 Jul 2;9:1519. doi: 10.3389/fimmu.2018.01519. eCollection 2018.
9
Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.天然杀伤T细胞在血液系统恶性肿瘤免疫调节中的作用：挖掘其在免疫治疗中的潜力
Front Immunol. 2017 Oct 23;8:1355. doi: 10.3389/fimmu.2017.01355. eCollection 2017.
10
Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.纳米颗粒：增强肿瘤抗原呈递，用于癌症的疫苗和免疫治疗。
Nanomedicine (Lond). 2017 Dec;12(23):2693-2706. doi: 10.2217/nnm-2017-0254. Epub 2017 Nov 3.
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
过继转移不变自然杀伤 T 细胞作为晚期黑色素瘤的免疫治疗：一项 I 期临床试验。
Clin Cancer Res. 2017 Jul 15;23(14):3510-3519. doi: 10.1158/1078-0432.CCR-16-0600. Epub 2017 Feb 13.
4
Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine.采用多模态纳米疫苗提高抗原特异性细胞毒性 T 淋巴细胞的增殖。
Int J Nanomedicine. 2016 Nov 16;11:6103-6121. doi: 10.2147/IJN.S112432. eCollection 2016.
5
Efficient Regeneration of Human Vα24 Invariant Natural Killer T Cells and Their Anti-Tumor Activity In Vivo.人Vα24不变自然杀伤T细胞的高效再生及其体内抗肿瘤活性
Stem Cells. 2016 Dec;34(12):2852-2860. doi: 10.1002/stem.2465. Epub 2016 Aug 1.
6
Glycolipid activators of invariant NKT cells as vaccine adjuvants.作为疫苗佐剂的不变自然杀伤T细胞糖脂激活剂。
Immunogenetics. 2016 Aug;68(8):597-610. doi: 10.1007/s00251-016-0925-y. Epub 2016 Jul 5.
7
Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.系统树突状细胞激活调节肿瘤微环境，并塑造由 CD8+ T 细胞介导的长期肿瘤特异性记忆。
Cancer Res. 2016 Jul 1;76(13):3756-66. doi: 10.1158/0008-5472.CAN-15-3219.
8
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents.合成糖脂激活自然杀伤 T 细胞作为免疫治疗剂。
Clin Transl Immunology. 2016 Apr 8;5(4):e69. doi: 10.1038/cti.2016.14. eCollection 2016 Apr.
9
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.CD62L+自然杀伤T细胞在体内具有持久的存续能力和抗肿瘤活性。
J Clin Invest. 2016 Jun 1;126(6):2341-55. doi: 10.1172/JCI83476. Epub 2016 May 16.
10
Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.α-GalCer 类似物与 TLR4 激动剂联合给药可诱导强烈的 CD8(+) T 细胞对 PyCS 蛋白和 WT-1 抗原的反应，并激活记忆样效应性 NKT 细胞。
Clin Immunol. 2016 Jul;168:6-15. doi: 10.1016/j.clim.2016.04.014. Epub 2016 Apr 27.